JP2024518426A5 - - Google Patents
Info
- Publication number
- JP2024518426A5 JP2024518426A5 JP2023568475A JP2023568475A JP2024518426A5 JP 2024518426 A5 JP2024518426 A5 JP 2024518426A5 JP 2023568475 A JP2023568475 A JP 2023568475A JP 2023568475 A JP2023568475 A JP 2023568475A JP 2024518426 A5 JP2024518426 A5 JP 2024518426A5
- Authority
- JP
- Japan
- Prior art keywords
- aciminib
- pharmaceutically acceptable
- acceptable salt
- combination
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187023P | 2021-05-11 | 2021-05-11 | |
| US63/187,023 | 2021-05-11 | ||
| PCT/IB2022/054321 WO2022238884A1 (en) | 2021-05-11 | 2022-05-10 | Dosing regimens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518426A JP2024518426A (ja) | 2024-05-01 |
| JP2024518426A5 true JP2024518426A5 (https=) | 2025-05-01 |
Family
ID=81846537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568475A Pending JP2024518426A (ja) | 2021-05-11 | 2022-05-10 | 投与レジメン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240245666A1 (https=) |
| EP (1) | EP4337205A1 (https=) |
| JP (1) | JP2024518426A (https=) |
| KR (1) | KR20240006600A (https=) |
| CN (1) | CN117396202A (https=) |
| CA (1) | CA3218550A1 (https=) |
| IL (1) | IL308095A (https=) |
| WO (1) | WO2022238884A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120239604A (zh) * | 2023-11-01 | 2025-07-01 | 深圳市塔吉瑞生物医药有限公司 | 治疗白血病的方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20161416A1 (es) * | 2012-05-15 | 2017-01-08 | Novartis Ag | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 |
-
2022
- 2022-05-10 WO PCT/IB2022/054321 patent/WO2022238884A1/en not_active Ceased
- 2022-05-10 US US18/559,859 patent/US20240245666A1/en active Pending
- 2022-05-10 IL IL308095A patent/IL308095A/en unknown
- 2022-05-10 JP JP2023568475A patent/JP2024518426A/ja active Pending
- 2022-05-10 EP EP22725540.3A patent/EP4337205A1/en active Pending
- 2022-05-10 KR KR1020237041919A patent/KR20240006600A/ko active Pending
- 2022-05-10 CN CN202280034821.XA patent/CN117396202A/zh active Pending
- 2022-05-10 CA CA3218550A patent/CA3218550A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024133475A5 (https=) | ||
| JP2022545835A5 (https=) | ||
| JP2024516363A5 (https=) | ||
| JP2024516795A5 (https=) | ||
| CN106535895A (zh) | 丁型肝炎病毒感染的治疗 | |
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2021509395A5 (https=) | ||
| KR20240032789A (ko) | 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물 | |
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| JP2024517085A5 (https=) | ||
| JP2024518426A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| JP2021522246A5 (https=) | ||
| JP2004525143A5 (https=) | ||
| JP2025517509A5 (https=) | ||
| TW202110448A (zh) | Ｐａｒｐ抑制劑聯合ｖｅｇｆｒ抑制劑用於治療卵巢癌或乳腺癌的用途 | |
| JP2022177119A5 (https=) | ||
| JP2022502450A5 (https=) | ||
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| JP2022504435A5 (https=) | ||
| JP2022524819A (ja) | カプシド集合調節剤固体製剤 | |
| JP2008501023A (ja) | 小児患者での癌の治療 | |
| JP2025511402A5 (https=) | ||
| JP2025511401A5 (https=) | ||
| CA2480275A1 (en) | Statin therapy for enhancing cognitive maintenance |